MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

37Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.

Cite

CITATION STYLE

APA

Varshney, J., & Subramanian, S. (2015, June 17). MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics. Frontiers in Molecular Biosciences. Frontiers Media S.A. https://doi.org/10.3389/fmolb.2015.00031

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free